Barcelona, Spain. October 27, 2018.
The REGEnLIFE company participated on October, 27thto the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Barcelona, Spain. Clinical trial teams worldwide discussed new results for the development of the next generation of treatments for Alzheimer’s Disease in order to identify new candidate therapeutic strategies. In this context, REGEnLIFE seized this opportunity to feature their latest results from their study regarding the impact of photobiomodulation RGn530 device on gut microbiota in a mouse model of Alzheimer’s disease. The encouraging results could pave the way for pilot clinical trials.
A brain-gut axis hypothesis
Following the rationale “thinking beyond the brain”, REGEnLIFE previously elaborated a phototherapeutic protocol based on the simultaneous exposition of head and abdomen. The company previously showed encouraging results following this procedure, published in Alzheimer’s and dementia: Translational Research & Clinical Interventions (see publication : G. Blivet et al., Alzheimers’ and Dement (NY) 4 (2018) 54-63). This study showed the most striking results on cognitive performance in mice and pathological markers when mice were treated with the device both on the head and abdomen compared with one site of exposition either the head or the abdomen. Following the growing number of scientific publications pointing out the implication of the microbiota influence in the pathology of the Alzheimer’s disease, the team wanted to analyze further the hypothesis of a ‘Gut-Brain axis synergy of effect’.
In collaboration with Amylgen (Montpellier, France) and Vaiomer (Toulouse, France), results showed that the microbiota was deeply affected in an Alzheimer’s mouse model. AD Mice displayed a strong caecal microbiota dysbiosis with several bacterial communities affected such as the Firmicutes and Bacteroidetes. Interestingly, the RGn530 treatment, applied on both head and abdomen, not only strongly impacted the microbial dysbiosis of mice, and seemed to reduce it, but reversed the pathological levels of both Firmicutes and Bacteroidetes with a tendency to restore the conditions seen in healthy mice. As previously demonstrated, this impact was associated with a total reversal of memory deficits and inflammation down-regulation.
Considering these preclinical results and the increasing number of publications suggesting that the microbiota dysbiosis could contribute to the pathology of many neurological conditions, the gut microbiota could be considered as a potential target for the treatment of the Alzheimer’s disease.
Announcement of a pilot clinical trial in Montpellier
REGEnLIFE also announced a pilot clinical trial on mild-to-moderate Alzheimer’s disease patients in order to evaluate the safety and efficacy of this medical device prototype on cognitive performances evolution.
This clinical trial is performed in the Montpellier University Hospital (France) with Dr. Audrey Gabelle as the Principal Investigator.